We hypothesized that CL22209 supplementation would reduce ovarian volume and follicle count, decrease the LH:FSH ratio and total testosterone (TT) levels, increase sex hormone-binding globulin (SHBG), and enhance insulin sensitivity (Homeostatic Model Assessment for Insulin Resistance [HOMA-IR]) compared with placebo. The gene discussed is BRD2; the disease is Insulin resistance.